Source:

Escherichia coli.

Molecular Weight:

6.0 kDa+/-10% determined by reduced SDS-PAGE

Purity:

Greater than 95% as determined by (a) Analysis by SEC-HPLC(b) Analysis by reducing and non-reducing SDS-PAGE Silver Stained gel

Biological activity:

The ED50, calculated by the dose-dependant proliferation of murine BALB/c 3T3 cells is less then 2 ng/ml, corresponding to a specific activity of 5.0×10ˆ5 IU/ mg.

AA Sequence:

MNSDSECPLS HDGYCLHDGV CMYIEALDKY ACNCVVGYIG ERCQYRDLKW WELR

Endotoxin:

Less than 0.1ng/μg (1 EU/μg) of recombinant human Epidermal Growth Factor (EGF) as determined by LAL test.

Formulation:

Recombinant human Epidermal Growth Factor (EGF) was lyophilized after extensive dialysis against 10mM Phosphate buffer, pH7.0, 200mM NaCl buffer.

Background:

Epidermal Growth Factor (EGF) is a polypeptide growth factor which stimulates the proliferation of a wide range of epidermal and epithelial cells. Recombinant human Epidermal Growth Factor (EGF) is a 6,200 Da protein containing 53 amino acid residues.

Usage:

This material is offered by USA Bioworld biotech for research, laboratory or further evaluation purposes. For research use only.

Physical Appearance:

Sterile Filtered White lyophilized (freeze-dried) powder.

Reconstitution:

It is recommended to reconstitute the lyophilized recombinant human Epidermal Growth Factor (EGF) in sterile 18 MΩ-cm H2O not less than 100 µg/ml, which can then be further diluted to other aqueous solutions.

Storage:

Lyophilized recombinant Human Epidermal Growth Factor (rhEGF) remains stable up to 12 months at -80°C from date of receipt. Upon reconstitution, rhEGF should be stable up to 4 weeks at 4°C or up to 6 months at -20°C.